ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating
CEO & Managing Director, Dr Tony Keating
Source: Business News
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ResApp Health (RAP) has updated the market on its March quarter activities
  • During the quarter, ResApp received TGA approval for its ResAppDx-EU device
  • This device uses machine learning algorithms to analyse a patient’s cough sounds to diagnose diseases and provide quick and accurate information
  • ResApp also announced it integrated ResAppDx-EU with two leading telehealth companies
  • The company then delivered its handheld and wearable prototypes for testing
  • Finally, at the beginning of April, ResApp announced the launch of SleepCheck, which is expected to be launched in the current quarter
  • SleepCheck analyses a patient’s breathing and snoring sounds during sleep to determine their risk of developing sleep apnoea
  • ResApp is up a slight 2.86 per cent on the market this morning and shares are trading for 18 cents each

ResApp Health (RAP) has updated the market on its March quarter activities.

During the period, the company primarily focused on commercialising its product suite, receiving regulatory approvals, and delivering prototypes.

“We have begun to make great progress on the commercialisation of our suite of products,” Managing Director and CEO Tony Keating commented.

“During the quarter, we agreed on our first set of commercial terms for the use of ResAppDx-EU in telehealth, which we were pleased to announce are within our previously targeted range of $5-$10 per test,” he said.

“The COVID-19 pandemic has shone a bright light on respiratory disease and, in particular, the telehealth industry, where we have seen an explosion in the number of telehealth consultants taking place globally,” he added.

ResAppDx regulatory approvals

In mid-February, ResApp received Australian Therapeutic Goods Administration (TGA) approval for its ResAppDx-EU device.

ResAppDx-EU is the company’s mobile software app that is used by clinicians for the diagnosis of multiple respiratory problems.

The software uses machine learning algorithms to analyse a patient’s cough sounds to diagnose diseases and provide quick and accurate information.

It is a software-only solution that can run on smartphones, meaning that it does not require any additional hardware or accessories.

However, during the quarter, ResApp was advised by the U.S. Food and Drug Administration (FDA) that its De Novo classification request for ResAppDx-US had not been approved.

The U.S. FDA claimed it needed more information about how the benefits of the device outweighed the risks.

ResApp says it’s now working closely with regulatory consultants to request a meeting with the FDA to work out the next steps.


Just before the cut-off date for quarter three on March 30, ResApp announced that it had integrated its respiratory app with Coviu’s telehealth platform.

Coviu is Australia’s leading telehealth software company, and its platform makes it easy for clinicians to offer their services directly to patients via video consultation.

Both ResApp and Coviu signed a binding term sheet and agreed to a testing fee of between $5 and $10 per ResAppDx-EU test.

A week before that, ResApp also entered a Joint Development Agreement with Phenix Health to integrate ResAppDx-EU into Phenix’s telehealth platform.

Phenix Health is a mobile clinic software developer that provides an online virtual health clinic.

ResApp is aiming for ResAppDx-EU to appear on both Coviu and Phenix before the end of this financial year.

Launch of SleepCheck

On April 1, ResApp announced that SleepCheck would be launched on the App Store in Australia and the U.K. during quarter four of this financial year.

SleepCheck offers clinically accurate algorithms to assess a person’s risk of obstructive sleep apnoea. It does this by analysing their breathing and snoring sounds during sleep.

Just like ResAppDx-EU, SleepCheck does not require any additional accessories or hardware; just a smartphone.

Sleep apnoea is when the air stops flowing to a person’s lungs for more than 10 seconds during sleep.

If those with sleep apnoea are left untreated then it can lead to heart disease, hypertension, stroke, and type 2 diabetes.

Prototypes delivered

Similarly, in mid-February, ResApp successfully completed testing its handheld and wearable prototype devices.

These devices are easy-to-wear platforms which continuously monitor patients with a chronic respiratory disease for up to three days.

These prototypes were given to U.K.-based medical device companies, Avanti Med and OSI Electronics, for functional testing.

Capital raise

Finally, ResApp successfully completed a $5 million capital raise to speed-up its European commercialisation during the quarter.

Approximately 25 million new ordinary shares were issued to institutional and sophisticated investors at a price of 20 cents per share.

Cash balance

At the end of the March quarter, ResApp had a cash balance of $6.9 million, which is an increase of $3 million from the previous quarter.

Cash outflows were $1.6 million, which is mainly associated with costs relating to research and development, and staff.

ResApp is up a slight 2.86 per cent on the market this morning and shares are trading for 18 cents each at 10:48 am AEST.

RAP by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…